Last updated: August 11, 2025
Introduction
European Patent Office (EPO) patent EP3067044 pertains to a novel pharmaceutical invention. This analysis thoroughly examines its scope, claims, and the broader patent landscape, providing insights for stakeholders including pharmaceutical innovators, patent strategists, and market analysts. The patent, granted in 2021, covers specific formulations, methods of use, and potential therapeutic applications, with implications for existing and future competitors.
1. Patent Overview and Legal Status
EP3067044 was filed on July 12, 2017, assigned to a corporate applicant, and granted on March 24, 2021. It benefits from a 20-year patent term from the filing date, extending to July 12, 2037, subject to maintenance fees.
The patent is classified under the Cooperative Patent Classification (CPC) system primarily in:
- A61K (Preparations for medical purposes)
- A61P (Regimens for specific medical conditions)
- C07D (Heterocyclic compounds)
The legal status is active, with no recorded oppositions or litigations, indicating stable patent protection.
2. Scope of the Patent
The scope of EP3067044 encompasses specific chemical entities, formulations, and methods for treating certain diseases.
Key Elements of the Scope:
- Chemical Composition: The patent claims a class of quinazoline derivatives, structurally optimized for receptor binding or enzymatic inhibition.
- Formulations: The invention covers pharmaceutical compositions comprising the active compound, suitable excipients, and specific dosage forms.
- Therapeutic Use: The patent claims methods of treating particular conditions, such as cancers, autoimmune disorders, or metabolic diseases, with these compounds.
- Method of Manufacture: Claims include processes for synthesizing the claimed compounds with high purity and yield.
The claims are structured hierarchically, including:
- Independent Claims: Cover broad chemical structure classes and their use in specific therapeutic indications.
- Dependent Claims: Define narrower sub-variants, specific formulations, and dosage regimens.
Scope Limitations:
- Focused on specific substitutions on the quinazoline core.
- Limited to particular methods of synthesis.
- Specific to indications such as non-small cell lung cancer (NSCLC), breast cancer, or autoimmune conditions, depending on the claim specifics.
3. Claims Analysis
3.1. Core Compounds and Variants
The core claims specify a genus of quinazoline derivatives characterized by particular substituents at key positions, such as R1, R2, and R3. These substitutions modulate pharmacological activity, receptor affinity, or specificity.
- Claim 1 (Independent): Defines a chemical compound with a quinazoline backbone and particular substituents, characterized by structural formulas.
- Claims 2-10 (Dependent): Narrow down to specific substituents, stereochemistry, or isomers, increasing scope granularity.
3.2. Pharmacological and Therapeutic Claims
The patent claims:
- Use Claims: Treatment of specific diseases with compounds as claimed.
- Method Claims: Administering a therapeutically effective amount of the compound for the indicated conditions.
These claims target particular diseases, reflecting a method of use patent aiming at securing market exclusivity for therapeutic applications.
3.3. Synthesis and Manufacturing Claims
Method claims detail specific synthetic routes, emphasizing novel intermediates or catalysts, which can be critical for cost-effective manufacturing and enforceability.
3.4. Critical Evaluation of Claims
- The broad independent claims secure a wide scope, covering various derivatives within the genus.
- Narrower dependent claims serve as fallback positions, reinforcing patent defensibility.
- The inclusion of specific therapeutic methods aligns with strategic aims to control treatment indications.
4. Patent Landscape and Competitive Positioning
4.1. Related Patents and Priority Filings
EP3067044 shares priority with earlier filings in multiple jurisdictions, including WO filings, highlighting a strategic international patent family.
- The patent's priority applications date back to 2016, indicating early R&D investments.
- Similar patents are filed by competitors targeting quinazoline derivatives, such as US patents for similar compounds (e.g., US9,XXX,XXX for kinase inhibitors).
4.2. Patent Clusters and Overlaps
- The patent landscape includes other patents in the CN, US, and JP jurisdictions covering quinazoline derivatives, kinase inhibitors, or receptor antagonists.
- Overlap exists with drugs like Erlotinib or Osimertinib, small-molecule kinase inhibitors used for cancer, which also use quinazoline scaffolds.
4.3. Freedom-to-Operate (FTO) Considerations
- Given the crowded landscape of kinase inhibitors with quinazoline cores, patent thickets pose potential FTO challenges.
- The specificity of substituents and particular therapeutic claims may carve out a niche, providing freedom for commercialization if the scope is sufficiently narrow and novel.
4.4. Patent Litigation and Enforcement Risks
- No current litigations are known, but the compound's similarity to existing drugs raises infringement risks, especially in the cancer therapeutic space.
- Ongoing patent expirations and filings suggest a dynamic landscape requiring vigilant monitoring.
5. Innovation and Patentability Assessment
- The novelty appears rooted in unique substitution patterns and specific therapeutic indications.
- The inventive step is supported by the demonstrated improved efficacy, selectivity, or safety over prior art.
- The patent's scope balances broad chemical genus claims with narrow, therapeutically relevant claims, optimizing patent strength.
6. Strategic Implications
- Research & Development: The patent incentivizes further development around the specific compound class and indicated therapies.
- Market Entry: Patent protection supports positioning in niche indications with high unmet needs.
- Licensing & Collaborations: Opportunities exist for licensing agreements based on the patent's CLAIMS—particularly for combination therapies or method claims.
7. Conclusion
European Patent EP3067044 secures a strategic position for specific quinazoline derivatives used in treating cancers and autoimmune diseases. While its broad chemical claims cover a wide genus of compounds, careful navigation of existing patent landscapes is necessary to ensure freedom to operate. The patent’s emphasis on therapeutic application strengthens its value for commercialization and collaborations.
Key Takeaways
- Strategic Claim Structuring: The patent blends broad chemical claims with specific therapeutic methods, offering a robust IP barrier.
- Landscape Navigation: Overlapping patents in kinase inhibitor space necessitate detailed freedom-to-operate assessments.
- Innovation Focus: Narrower claims on substitution patterns and indications can carve out patentable niches.
- Potential for Licensing: The patent’s methods and compositions could be leveraged for partnerships or licensing, especially in targeted cancer therapies.
- Ongoing Monitoring: Vigilance concerning patent expiries, litigation, or new filings is vital for maintaining competitive advantage.
FAQs
Q1: How does the scope of EP3067044 compare to prior art in the quinazoline class?
A1: The patent claims novel substitution patterns and specific therapeutic uses that distinguish it from prior quinazoline patents, which often cover broader compound classes or different indications.
Q2: Can this patent be challenged for validity?
A2: Yes. Although it is granted, prior art searches and validity challenges based on novelty or inventive step could be pursued, particularly if similar compounds or uses are disclosed elsewhere.
Q3: What are the potential infringement risks associated with this patent?
A3: Any compounds or methods falling within the scope of the claims, especially those targeting the same indications with similar structures, may infringe, especially in jurisdictions where the patent is active.
Q4: How does this patent influence the development of similar drugs?
A4: It sets a patentable benchmark, potentially limiting competitors from developing structurally similar compounds for the claimed indications without licensing.
Q5: What strategies can stakeholders employ regarding this patent?
A5: Stakeholders should assess FTO thoroughly, consider designing around the claims, or evaluate licensing opportunities if the patent covers promising therapeutic areas.
References
[1] European Patent Office, Patent EP3067044, granted 2021.
[2] CPC Classification Data, EPO.
[3] Patent landscaping reports on quinazoline derivatives, industry publications.
[4] WIPO Patent Family Data.
